Valuation: Valneva SE

Market Cap 480M 540M 448M 408M 770M 51.93B 777M 5.42B 2.1B 26.55B 2.03B 1.98B 85.21B P/E 2026 *
-5.81x
P/E 2027 * 9.16x
Enterprise Value 614M 691M 573M 522M 985M 66.4B 994M 6.93B 2.69B 33.95B 2.59B 2.54B 109B EV / Sales 2026 *
4.06x
EV / Sales 2027 * 1.91x
Free-Float
89.26%
Yield 2026 *
-
Yield 2027 * -
1 day-3.06%
1 week-5.28%
Current month-6.61%
1 month-9.80%
3 months+12.59%
6 months-10.31%
Current year-31.93%
1 week 2.48
Extreme 2.484
2.81
1 month 2.48
Extreme 2.484
3.14
Current year 2.03
Extreme 2.033
5.15
1 year 2.03
Extreme 2.033
5.18
3 years 1.73
Extreme 1.726
7.17
5 years 1.73
Extreme 1.726
29.7
10 years 1.73
Extreme 1.726
29.7
Manager TitleAgeSince
Chief Executive Officer 62 -
Director of Finance/CFO 56 28/07/2021
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 62 19/12/2023
Director/Board Member 75 06/03/2013
Chairman 65 19/12/2023
Date Insider Type Main position Quantity % Market Cap. Importance
27/01/26 Sell

Chief Technology Officer

11,800 0.0069%
26/01/26 Sell

Chief Financial Officer

11,800 0.0069%
19/01/26 Exercice

Chief Technology Officer

82,899 0.0482%
Change 5-day change 1-year change 3-year change Capi.($)
-3.06%-5.28%-50.28%-54.30% 557M
+4.16%+3.04%+49.37%+94.17% 74.41B
-3.11%-2.32%+23.28%+77.03% 59.26B
+0.89%-0.77%+5.80%+32.89% 47.14B
-0.96%-6.11%+26.70%+31.24% 42.91B
+0.36%+3.39%+350.59%+646.53% 44.13B
-0.20%-0.53%+6.84%+99.07% 40.79B
-0.54%+2.93%+9.50%+50.41% 30.77B
-2.68%+5.11%+33.11%+19.50% 29.31B
+2.33%-8.58%-24.55%+340.08% 23.71B
Average -0.28%-0.81%+43.04%+133.66% 39.3B
Weighted average by Cap. +0.24%-0.41%+58.21%+145.53%

Financials

2026 *2027 *
Net sales 151M 170M 141M 128M 242M 16.34B 245M 1.71B 661M 8.35B 638M 624M 26.81B 283M 319M 264M 241M 455M 30.66B 459M 3.2B 1.24B 15.67B 1.2B 1.17B 50.3B
Net income -81.11M -91.29M -75.71M -69M -130M -8.78B -131M -916M -355M -4.49B -343M -335M -14.4B 53.07M 59.73M 49.53M 45.15M 85.15M 5.74B 85.94M 599M 232M 2.94B 224M 219M 9.42B
Net Debt 134M 150M 125M 114M 215M 14.47B 217M 1.51B 585M 7.4B 565M 553M 23.74B 62.48M 70.32M 58.31M 53.15M 100M 6.76B 101M 706M 273M 3.46B 264M 258M 11.09B
Logo Valneva SE
Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. Valneva takes a highly specialized and targeted approach, applying its deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. Valneva has a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently markets three proprietary travel vaccines. Revenues from its growing commercial business help fuel the continued advancement of its vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world's most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against other global public health threats.
Employees
620
Date Price Change Volume
02/10/26 €2.531 -3.06% 620,259
01/10/26 €2.611 -3.65% 352,536
30/09/26 €2.710 +0.86% 221,037
29/09/26 €2.687 -3.00% 218,548
28/09/26 €2.770 +4.14% 225,093
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
2.611EUR
Average target price
6.193EUR
Spread / Average Target
+137.18%

Quarterly revenue - Rate of surprise